Factors associated with risk of major adverse cardiovascular events in patients with rheumatoid arthritis: a nationwide, population-based, case-control study.
Yen-Ju ChenShih-Chia LiuKuo-Lung LaiKuo-Tung TangChing-Heng LinYi Ming ChenChih-Wei TsengYu-Mei ChangDonald F GotcherChuang-Chun ChiouShao-Jen WengHsin-Hua ChenPublished in: Therapeutic advances in musculoskeletal disease (2021)
This population-based case-control study revealed that the use of golimumab, abatacept, hydroxychloroquine, and methotrexate were associated with a decreased risk of MACE development in newly diagnosed RA patients, while the use of cyclosporin, NSAIDs, and antiplatelet agents, and comorbidities, including hypertension, diabetes, hyperlipidemia without lipid-lowering agent therapy, ischemic heart disease, and COPD, were associated with an increased risk of MACE development in RA patients.
Keyphrases
- newly diagnosed
- end stage renal disease
- cardiovascular events
- chronic kidney disease
- cardiovascular disease
- type diabetes
- blood pressure
- coronary artery disease
- peritoneal dialysis
- emergency department
- stem cells
- ankylosing spondylitis
- single cell
- insulin resistance
- patient reported outcomes
- metabolic syndrome
- adipose tissue
- high fat diet
- disease activity
- skeletal muscle
- air pollution
- bone marrow
- systemic sclerosis